Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1712 studies found for:    Open Studies | "Lymphatic Diseases"
Show Display Options
Rank Status Study
21 Unknown  Ultrasonographic Differentiation Between Kikuchi's Disease and Lymphoma in Patients With Cervical Lymphadenopathy
Conditions: Lymphoma;   Kikuchi's Disease
22 Not yet recruiting A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Chlorambucil;   Drug: Obinutuzumab
23 Not yet recruiting Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia
Conditions: Acute Lymphocytic Leukemia;   Acute Myeloid Leukemia
Intervention: Drug: Daunorubicin
24 Not yet recruiting Study of ME-401 in Subjects With Relapsed/Refractory CLL/SLL or FL
Conditions: Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma;   Follicular Lymphoma
Intervention: Drug: ME-401
25 Not yet recruiting Study of Pharmacokinetics and Preliminary Efficacy in Patients With Niemann-Pick C1
Condition: Niemann-Pick Disease, Type C1
Intervention: Drug: Hydroxypropyl-beta-cyclodextrin
26 Not yet recruiting Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients
Condition: Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Drug: ruxolitinib;   Drug: ibrutinib
27 Recruiting L-DEP as an Initial Treatment for EBV-HLH
Condition: Hemophagocytic Lymphohistiocytosis
Interventions: Drug: Pegaspargase;   Drug: doxorubicin hydrochloride liposome injection;   Drug: etoposide;   Drug: methylprednisolone;   Drug: Etoposide;   Drug: dexamethasone
28 Not yet recruiting Thiopurine Enhanced ALL Maintenance Therapy
Condition: Acute Lymphoblastic Leukemia
Intervention: Drug: Thioguanine (oral)
29 Not yet recruiting Phase I/II Study of Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R(2)) In Primary Effusion Lymphoma or KSHV-Associated Large Cell Lymphoma
Conditions: Primary Effusion Lymphoma;   B-Cell Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Rituximab;   Drug: Prednisone;   Drug: Etopside;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide on day 10 (for 6 cycles), each patient will get a 750 mg/m2 dose.
30 Not yet recruiting Ibrutinib Plus Venetoclax in Patients With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
Conditions: Leukemia, Chronic Lymphocytic;   Lymphoma, Small Lymphocytic
Interventions: Drug: ibrutinib;   Drug: placebo to match ibrutinib;   Drug: venetoclax
31 Not yet recruiting Study to Evaluate Safety and Efficacy of Blinatuomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
Condition: B-Cell Non Hodgkin Lymphoma
Interventions: Drug: Blinatumomab;   Drug: Investigator's Choice Chemotherapy
32 Not yet recruiting Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Conditions: Lymphoma;   Neuroblastoma;   Brain Tumor;   Solid Tumor
Intervention: Drug: CUDC-907
33 Recruiting Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome
Condition: Lymphoblastic Leukemia, Acute, Childhood
Intervention: Drug: Tocilizumab
34 Recruiting PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation
Condition: Lymphoma
Interventions: Drug: PEG-rhG-CSF;   Drug: rhG-CSF
35 Recruiting Indolent Non Follicular Lymphomas Prognostic Project
Condition: Indolent B-Cell Lymphomas
Intervention: Other: Any treatment, watch and wait policy included
36 Recruiting Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK +
Condition: ALCL
Intervention: Other: Blood sample
37 Not yet recruiting tTF-NGR Study Phase I
Conditions: Malignant Solid Tumors;   Lymphomas
Intervention: Biological: tTF-NGR
38 Not yet recruiting Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive Cluster of Differentiation(CD) 20-Positive Post-Transplant Lymphoproliferative Disorder
Conditions: Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorder;   Monomorphic Post-Transplant Lymphoproliferative Disorder;   Polymorphic Post-Transplant Lymphoproliferative Disorder
Interventions: Biological: Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes;   Other: Laboratory Biomarker Analysis;   Biological: Rituximab
39 Recruiting Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas
Conditions: Chronic Lymphocytic Leukemia;   B-Cell Lymphoma
Interventions: Drug: DTRMWXHS-12;   Drug: DTRM-505;   Drug: DTRM-555
40 Not yet recruiting Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
Condition: Diffuse Large B-cell Lymphoma (DLBCL)
Intervention: Drug: MAK683

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years